Standard cytotherapy + RAMUCIRUMAB for adenocarcinoma

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 11 Aug 2014: Trial registered, NCT02213289
  2. 20 Jan 2015: Trial started, NCT02213289

The trials

NCT02213289: PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression

State
Completed
Phase
Phase 2
People
80 taking part
Started
20 Jan 2015
Primary completion
1 Feb 2020
Arms
ITT-PTS: Personalized Treatment Strategy (MAPK/PIK3CA aberrant), ITT-PTS: Personalized Treatment Strategy (All negative)
Results
Posted on the registry
  1. 11 Aug 2014: Trial registered
  2. 20 Jan 2015: Trial started
  3. 20 Aug 2020: Trial completed
  4. 8 Apr 2021: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.